Vertex Pharmaceuticals (WBO:VRTX) Cyclically Adjusted Revenue per Share: €26.35 (As of Mar. 2026)


WBO:VRTX Vertex Pharmaceuticals Inc WBO:VRTX
85 GF Score
Price €424.75
GF Value €437.40
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share?

Vertex Pharmaceuticals WBO:VRTX +0.27% 85 Cyclically Adjusted Revenue per Share is €26.35 as of Mar. 2026. GuruFocus rates WBO:VRTX with a GF Score™ of 85/100 and a GF Value™ of €437.40 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was €10.081. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €26.35 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Vertex Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 19.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 21.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 24.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 25.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vertex Pharmaceuticals was 29.90% per year. The lowest was -4.70% per year. And the median was 16.05% per year.

As of today (2026-07-12), Vertex Pharmaceuticals's current stock price is €424.75. Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €26.35. Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 16.12.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vertex Pharmaceuticals was 37.95. The lowest was 13.63. And the median was 21.29.


Vertex Pharmaceuticals  (WBO:VRTX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=424.75/26.35
=16.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vertex Pharmaceuticals was 37.95. The lowest was 13.63. And the median was 21.29.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.47 15.10 18.09 23.66 25.06

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.72 22.88 23.73 25.06 26.35

WBO:VRTX vs REGN, ALNY, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


WBO:VRTX
85GF Score
Vertex Pharmaceuticals Inc WBO:VRTX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vertex Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=10.081/330.2130*330.2130
=10.081

Current CPI (Mar. 2026) = 330.2130.

Vertex Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.571 241.018 2.152
201609 1.505 241.428 2.058
201612 1.774 241.432 2.426
201703 2.687 243.801 3.639
201706 1.925 244.955 2.595
201709 1.938 246.819 2.593
201712 2.146 246.524 2.875
201803 2.010 249.554 2.660
201806 2.490 251.989 3.263
201809 2.588 252.439 3.385
201812 2.944 251.233 3.870
201903 2.920 254.202 3.793
201906 3.206 256.143 4.133
201909 3.311 256.759 4.258
201912 4.850 256.974 6.232
202003 5.203 258.115 6.656
202006 5.139 257.797 6.583
202009 4.945 260.280 6.274
202012 5.117 260.474 6.487
202103 5.530 264.877 6.894
202106 5.703 271.696 6.931
202109 6.494 274.310 7.817
202112 7.140 278.802 8.457
202203 7.385 287.504 8.482
202206 8.031 296.311 8.950
202209 9.085 296.808 10.107
202212 8.351 296.797 9.291
202303 8.521 301.836 9.322
202306 8.837 305.109 9.564
202309 8.930 307.789 9.581
202312 8.852 306.746 9.529
202403 9.480 312.332 10.023
202406 9.523 314.175 10.009
202409 9.569 315.301 10.022
202412 10.808 315.605 11.308
202503 9.875 319.799 10.197
202506 9.928 322.561 10.164
202509 10.175 324.800 10.345
202512 10.633 324.054 10.835
202603 10.081 330.213 10.081

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €26.35 mean?
Vertex Pharmaceuticals (WBO:VRTX) has a Cyclically Adjusted Revenue per Share of €26.35 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Vertex Pharmaceuticals' current Cyclically Adjusted Revenue per Share is €26.35. Overall, Vertex Pharmaceuticals has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to REGN and ALNY?
Vertex Pharmaceuticals' Cyclically Adjusted Revenue per Share of €26.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Cyclically Adjusted Revenue per Share is €26.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €437.40, compared to a current price of €424.75 — trading 2.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €26.35. Vertex Pharmaceuticals' overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current Cyclically Adjusted Revenue per Share is €26.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €424.75 is trading 2.9% below its estimated GF Value™ of €437.40. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for WBO:VRTX:

  • Cyclically Adjusted Revenue per Share: €26.35
  • GF Value™: €437.40 vs. price of €424.75 (2.9% below fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
85GF Score

Get the complete analysis for WBO:VRTX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€424.75
Price
€437.40
GF Value